Catalyst
Slingshot members are tracking this event:
Novartis' (NVS) Gets Priority Review for Ribociclib Marketing Application in First-Line Treatment of HR+/HER2- Advanced Breast Cancer
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| NVS |
|
|
||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Nov 01, 2016
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Priority Review, Ribociclib, Marketing Application, First-line Treatment, Hr+/her2- Advanced Breast Cancer
